Analysis of treatment satisfaction and adherence among patients with type 2 diabetes

Cover Page

Cite item


Background: Low treatment adherence in patients with type 2 diabetes mellitus (T2DM) hinders the effective use of anti-diabetic agents and the achievement of glycemic control, reducing their quality of life and outcomes. Assessment of treatment adherence can help to identify and manage factors and barriers that affect therapy and treatment satisfaction.

Aim: To assess the treatment adherence of patients with T2DM, to identify the main barriers to adherence, and patient satisfaction with the treatment.

Materials and methods: FORSIGHT-T2DM was a  Russian multiregional, multicenter observational epidemiological study in 2014 patients with T2DM. The patients were assessed with the FORSIGHT- T2DM Patient Questionnaire, Moriski Medication Adherence Scale (MMAS), and Diabetes Treatment Satisfaction Questionnaire (DTSQ).

Results: The mean (± SD) treatment adherence estimated using the MMAS was 5.86±1.39 points. The main barriers to adherence were high treatment costs, medication side effects, forgetfulness when taking drugs, complexity of the therapy or treatment regimen. The average number of daily medications was four. There was also a lack of contact with a doctor, poor awareness of the disease and its complications. Ninety (90) per cent of the respondents trusted the recommendations from their doctors, 7.6% followed the advice of relatives or friends. The patient's choice of medication was influenced by information about its effectiveness, its cost, and reimbursement, ease of administration, and information on the absence of side effects. Seventy eight (78) per cent of the respondents were “completely” or “rather” satisfied with their treatment. About 15% of patients rated the quality of care as unsatisfactory.

Conclusion: The results of the study identified an intermediate level of treatment adherence in most patients with T2DM, as well as multiple adherence barriers, including comorbidities and the need for continuous intake of various agents. Most patients showed high treatment satisfaction, which could be due to the high availability of outpatient consultations by an endocrinologist and inpatient treatment, free access to anti-diabetic medications. However, it may also be a  result of biased assessment of problems due to insufficient patient awareness of the therapy goals and a low level of knowledge about their disease. To study the factors affecting the adherence to medical recommendations among patients with T2DM, it is necessary to develop a  specific questionnaire for this patient category, which would allow for an evaluation both drug intake and other aspects of their comprehensive treatment, including the identification and analysis of the main barriers to adherence.

About the authors

M. F. Kalashnikova

I.M. Sechenov First Moscow State Medical University

Author for correspondence.
ORCID iD: 0000-0002-1282-2576

Marina F. Kalashnikova – MD, PhD, Associate Professor, Chair of Endocrinology, Faculty of General Medicine

1/1 Pogodinskaya ul., Moscow, 119121

Russian Federation

I. B. Bondareva

Peoples' Friendship University of Russia (RUDN University)

ORCID iD: 0000-0002-8436-8931

Irina B. Bondareva – MD, PhD, Doctor of Biol. Sci., Professor, Chair of General and Clinical Pharmacology

6 Miklukho-Maklaya ul., Moscow, 117198

Russian Federation

N. V. Likhodey

I.M. Sechenov First Moscow State Medical University

ORCID iD: 0000-0002-4680-0746

Natalia V. Likhodey – Endocrinologist, Department of Therapeutic Endocrinology No. 2, University Clinical Hospital No. 2

8/2 Trubetskaya ul., Moscow, 119991

Russian Federation

Yu. P. Sych

I.M. Sechenov First Moscow State Medical University

ORCID iD: 0000-0002-7000-0095

Yulia P. Sych – MD, PhD, Assistant Professor, Chair of Endocrinology, Faculty of General Medicine

8/2 Trubetskaya ul., Moscow, 119991

Russian Federation


  1. Дедов ИИ, Калашникова МФ, Белоусов ДЮ, Рафальский ВВ, Калашников ВЮ, Колбин АС, Языкова ДР, Иваненко ЛР. Фармакоэпидемиологические аспекты мониторинга здоровья пациентов с сахарным диабетом 2 типа: результаты Российского наблюдательного многоцентрового эпидемиологического исследования ФОРСАЙТ-СД 2. Сахарный диабет. 2016;19(6):443–56. doi: 10.14341/DM8146.
  2. Дедов ИИ, Калашникова МФ, Белоусов ДЮ, Колбин АС, Рафальский ВВ, Чеберда АЕ, Кантемирова МА, Закиев ВД, Фадеев ВВ. Анализ стоимости болезни сахарного диабета 2 типа в Российской Федерации: результаты Российского многоцентрового наблюдательного фармакоэпидемиологического исследования ФОРСАЙТ-СД2. Сахарный диабет. 2018;20(6):403–19. doi: 10.14341/DM9278.
  3. World Health Organization. Patient adherence [Internet]. 2009. Available from:
  4. Hochbaum G, Rosenstock I, Kegels S. Health Belief Model. 1st ed. United States Public Health Service; 1952.
  5. Лиходей НВ, Калашникова МФ, Лиходей ЕМ, Фадеев ВВ. Анализ факторов, препятствующих формированию приверженности лечению среди больных сахарным диабетом, и стратегий, способствующих ее повышению. Сахарный диабет. 2018;21(1):5–14. doi: 10.14341/DM8781.
  6. Devine F, Edwards T, Feldman SR. Barriers to treatment: describing them from a different perspective. Patient Prefer Adherence. 2018;12:129–33. doi: 10.2147/PPA.S147420.
  7. Atkinson MJ, Sinha A, Hass SL, Colman SS, Kumar RN, Brod M, Rowland CR. Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes. 2004;2:12. doi: 10.1186/1477-7525-2-12.
  8. Lam WY, Fresco P. Medication Adherence Measures: An Overview. Biomed Res Int. 2015;2015:217047. doi: 10.1155/2015/217047.
  9. Старостина ЕГ, Володина МН. Роль комплаентности в ведении больных диабетом. Русский медицинский журнал. 2015;(8):477–80.
  10. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986;24(1):67–74. doi: 10.1097/00005650-198601000-00007.
  11. Bradley C. Diabetes treatment satisfaction questionnaire. Change version for use alongside status version provides appropriate solution where ceiling effects occur. Diabetes Care. 1999;22(3):530–2. doi: 10.2337/diacare.22.3.530.
  12. Morisky DE, Ang A, Krousel-Wood M, Ward HJ. Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens (Greenwich). 2008;10(5):348–54. doi: 10.1111/j.1751-7176.2008.07572.x.
  13. Gellad WF, Grenard J, McGlynn EA. A Review of Barriers to Medication Adherence: A Framework for Driving Policy Options [Internet]. Santa Monica, CA: RAND Corporation; 2009. 52 p. Available from:
  14. Киштович АВ, Курбатова КА, Ионова ТИ. Апробация русскоязычной версии опросника удовлетворенности лечением диабета DTSQ. Вестник Межнационального центра исследования качества жизни. 2015;(25–26):51–5.
  15. Avramopoulos I, Moulis A, Nikas N. Glycaemic control, treatment satisfaction and quality of life in type 2 diabetes patients in Greece: The PANORAMA study Greek results. World J Diabetes. 2015;6(1):208–16. doi: 10.4239/wjd.v6.i1.208.
  16. Depablos-Velasco P, Salguero-Chaves E, Mata-Poyo J, Derivas-Otero B, García-Sánchez R, Viguera-Ester P. Quality of life and satisfaction with treatment in subjects with type 2 diabetes: results in Spain of the PANORAMA study. Endocrinol Nutr. 2014;61(1):18–26. English, Spanish. doi: 10.1016/j.endonu.2013.05.005.
  17. Nicolucci A, Cucinotta D, Squatrito S, Lapolla A, Musacchio N, Leotta S, Vitali L, Bulotta A, Nicoziani P, Coronel G; QuoLITy Study Group. Clinical and socio-economic correlates of quality of life and treatment satisfaction in patients with type 2 diabetes. Nutr Metab Cardiovasc Dis. 2009;19(1):45–53. doi: 10.1016/j.numecd.2007.12.005.
  18. Biderman A, Noff E, Harris SB, Friedman N, Levy A. Treatment satisfaction of diabetic patients: what are the contributing factors? Fam Pract. 2009;26(2):102–8. doi: 10.1093/fampra/cmp007.
  19. Ozder A, Sekeroglu M, Eker HH. Quality of life and satisfaction with treatment in subjects with type 2 diabetes: results from primary health care in Turkey. Int J Clin Exp Med. 2014;7(12):5715–22.
  20. Bener A, Al-Hamaq AO, Yousafzai MT, Abdul-Ghani M. Relationship between patient satisfactions with diabetes care and treatment. Niger J Clin Pract. 2014;17(2):218–25. doi: 10.4103/1119-3077.127562.
  21. Wang J, Bian RW, Mo YZ. Validation of the Chinese version of the eight-item Morisky medication adherence scale in patients with type 2 diabetes mellitus. J Clin Gerontol Geriatr. 2013;4(4):119–22. doi: 10.1016/j.jcgg.2013.06.002.
  22. Brown MT, Bussell J, Dutta S, Davis K, Strong S, Mathew S. Medication Adherence: Truth and Consequences. Am J Med Sci. 2016;351(4): 387–99. doi: 10.1016/j.amjms.2016.01.010.
  23. Кисляк ОА. Улучшение контроля артериальной гипертонии у лиц с высоким риском развития сердечно-сосудистых осложнений: возможности использования результатов программы АРГУС-2. Системные гипертензии. 2008;5(1):32–6.
  24. American College of Preventive Medicine. Medication adherence – improving health outcomes. A Clinical Reference [Internet]. 2011. Available from:
  25. Mahmoodi MR, Khanjani N. Barriers and Limitations to Obstacle Diabetes Self-Management with a Focus on Nutritional Literacy: Solutions and Opportunities. Critical Review and Research Synthesis. Crit Comm Biomed. 2020;1(1):e10008. doi: 10.18502/ccb.v1i1.2870.
  26. Lamarche L, Tejpal A, Mangin D. Self-efficacy for medication management: a systematic review of instruments. Patient Prefer Adherence. 2018;12:1279–87. doi: 10.2147/PPA.S165749.
  27. Старостина ЕГ. Биомедицинские и психосоциальные аспекты сахарного диабета и ожирения: взаимодействие врача и пациента и пути его оптимизации [диссертация]. М.: ГБУЗ МО МОНИКИ им. М.Ф. Владимирского; 2003. 396 с.

Copyright (c) 2020 Kalashnikova M.F., Bondareva I.B., Likhodey N.V., Sych Y.P.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies